Halozyme Therapeutics, Inc.

Total Valuation

Halozyme Therapeutics, Inc. carries a market capitalization of 12.94B, placing it among publicly traded companies globally. Its enterprise value stands at 10.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Halozyme Therapeutics, Inc. currently has 114.04M shares outstanding.

Valuation Ratios

Halozyme Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 22.25. The price-to-sales ratio is 5.53, and the price-to-book ratio stands at 62.18.

Enterprise Valuation

On an enterprise value basis, Halozyme Therapeutics, Inc. trades at an EV/EBITDA multiple of 10.37 and an EV/FCF ratio of 12.82. The EV/Sales ratio of 6.52 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.65 provides insight into valuation relative to core operating earnings.

Financial Position

Halozyme Therapeutics, Inc. maintains a current ratio of 2.71, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,495.48, indicating moderate leverage, while an interest coverage ratio of 51.50 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Halozyme Therapeutics, Inc. posts a return on equity of 173.67 and a return on invested capital of 31.94.

Taxes

Over the trailing twelve months, Halozyme Therapeutics, Inc. has paid 169.74M in income taxes, reflecting an effective tax rate of 29.10.

Stock Price Statistics

Halozyme Therapeutics, Inc.'s stock has gained approximately 43.77719% over the past 52 weeks. The 50-day moving average sits at 94.20, while the 200-day moving average is 75.30.

Income Statement

Over the trailing twelve months, Halozyme Therapeutics, Inc. generated 1.66B in revenue and converted that into 413.60M in net income, yielding earnings per share of 3.42. EBITDA reached 1.05B, while operating income came in at 930.79M.

Balance Sheet

Halozyme Therapeutics, Inc. holds 231.00M in cash and equivalents against 2.15B in total debt, resulting in a net debt position of 1.98B. Total book value stands at 143.54M, with working capital of 588.59M providing operational flexibility.

Cash Flow

Halozyme Therapeutics, Inc. produced 818.60M in operating cash flow over the past twelve months. After subtracting -12.37M in capital expenditures, free cash flow totaled 806.22M - equivalent to 6.86 per share.

Margins

Halozyme Therapeutics, Inc. operates with a gross margin of 82.42, reflecting its pricing power and cost economics. The operating margin of 55.95 and net profit margin of 24.86 provide insight into operational efficiency.

Dividends & Yields

Scores

Halozyme Therapeutics, Inc. posts an Altman Z-Score of 7.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.